Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension
- PMID: 2942387
- DOI: 10.2165/00003495-198600314-00023
Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension
Abstract
The heart adapts to increasing afterload, such as that which occurs in arterial hypertension, with an increase in wall thickness in order to bring wall stress back to normal. As a consequence, concentric left ventricular hypertrophy ensues. Hypertension as well as advancing age has been shown to be associated with an increase in posterior wall thickness. Accordingly, the prevalence of left ventricular hypertrophy becomes very high in the elderly and may occur in more than 50% of elderly hypertensive patients. Left ventricular hypertrophy is not merely a physiological process serving to compensate for the increased afterload. The Framingham study has indicated that patients with left ventricular hypertrophy are at an increased risk of sudden death and other cardiovascular morbidity and mortality. The risk for sudden death is 5 to 6 times higher in patients with left ventricular hypertrophy than in those without, regardless of levels of arterial pressure. By Holter monitoring of these patients it has been shown that those with left ventricular hypertrophy have a prevalence of premature ventricular contractions that is 40 to 50 times higher than those patients without left ventricular hypertrophy. In addition, patients with left ventricular hypertrophy rated substantially higher with regard to Lown's classes than those without. These data indicate that left ventricular hypertrophy is common, particularly in the elderly, and predisposes to ventricular ectopy, higher grade arrhythmias, and sudden death. Clearly, these considerations have to be taken into account when selecting antihypertensive therapy inasmuch as hypokalaemia, hypomagnesaemia, and other electrolyte shifts predisposing to ventricular arrhythmias must be scrupulously avoided.
Similar articles
-
Determinants of ventricular ectopy in hypertensive cardiac hypertrophy.Am Heart J. 1992 Jan;123(1):89-95. doi: 10.1016/0002-8703(92)90751-g. Am Heart J. 1992. PMID: 1530898
-
Risk reduction following regression of cardiac hypertrophy.Clin Exp Hypertens A. 1990;12(5):903-16. doi: 10.3109/10641969009073508. Clin Exp Hypertens A. 1990. PMID: 2145097 Review.
-
Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death.Am J Med. 1992 Aug 31;93(2A):21S-26S. doi: 10.1016/0002-9343(92)90291-i. Am J Med. 1992. PMID: 1387763 Review.
-
Left ventricular hypertrophy, arterial hypertension and sudden death.J Hypertens Suppl. 1990 Dec;8(7):S181-6. J Hypertens Suppl. 1990. PMID: 2151334 Review.
-
[Concentric left ventricular hypertrophy in patients with hypertension. When should ventricular hyperexcitability be searched for?].Arch Mal Coeur Vaiss. 1990 Jul;83(8):1107-10. Arch Mal Coeur Vaiss. 1990. PMID: 1701985 French.
Cited by
-
How does pressure overload cause cardiac hypertrophy and dysfunction? High-ouabain affinity cardiac Na+ pumps are crucial.Am J Physiol Heart Circ Physiol. 2017 Nov 1;313(5):H919-H930. doi: 10.1152/ajpheart.00131.2017. Epub 2017 Jul 21. Am J Physiol Heart Circ Physiol. 2017. PMID: 28733446 Free PMC article. Review.
-
Cinnamic acid alleviates hypertensive left ventricular hypertrophy by antagonizing the vasopressor activity and the pro-cardiac hypertrophic signaling of angiotensin II.Front Pharmacol. 2025 Feb 14;16:1555991. doi: 10.3389/fphar.2025.1555991. eCollection 2025. Front Pharmacol. 2025. PMID: 40028160 Free PMC article.
-
Ageing and its effects on the cardiovascular system.Drugs. 1990;39 Suppl 1:1-8. doi: 10.2165/00003495-199000391-00003. Drugs. 1990. PMID: 2407489 Review.
-
Atherosclerotic vascular disease is more prevalent among black ESKD patients on long-term CAPD in South Africa.BMC Nephrol. 2019 Oct 30;20(1):399. doi: 10.1186/s12882-019-1583-8. BMC Nephrol. 2019. PMID: 31666030 Free PMC article.
-
RyR2 Stabilizer Attenuates Cardiac Hypertrophy by Downregulating TNF-α/NF-κB/NLRP3 Signaling Pathway through Inhibiting Calcineurin.J Cardiovasc Transl Res. 2024 Jun;17(3):481-495. doi: 10.1007/s12265-023-10376-8. Epub 2024 Apr 23. J Cardiovasc Transl Res. 2024. PMID: 38652413
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials